PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2020–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Explore the portfolio See the ranking
6
Total patents granted
5
CPC technology areas
17.0
Avg claims per patent
-
5-year filing velocity

The verdict

Shanghai holds 6 US patents across 5 technology areas, rank #42,824 of 50,000 tracked assignees.

#42,824
of 50,000 US assignees by volume
Top 81%
by Innovation Score (26.2/100)
17.0
avg claims per patent

Portfolio overview

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd has been granted 6 US utility patents between 2020 and 2022, placing Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd at rank #42,824 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd is one of the more focused assignees in the PatentsView dataset. By volume, Shanghai sits between Shanghai Microport EP Medtech Co., Ltd. (6 patents, rank #42,820) and SHEI Chung HSIN IND. Co., Ltd. (6 patents, rank #42,828) - the closest US assignees by grant volume. The composite Innovation Score of 26.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2020 through 2022, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's 17.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd against peers pursuing similar technology classes.

Who files at Shanghai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Shanghai holds 6 patents at rank #42,824, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Shanghai

By rank, the assignees closest to #42,824 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Shanghai's primary technology class.

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

26 Top 81% higher than 19% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202020212022 1
USPTO utility patent grants by year · 2020–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 33.3%
2021 3 50.0%
2022 1 16.7%

Which technologies does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent most?

Top 5 of 5 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard

Where it ranks

Overall rank by patents

#42,824

Across all tracked assignees

Innovation Score

26.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd hold?
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd holds 6 US granted patents filed between 2020 and 2022, spanning 5 technology areas.
What is Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's Innovation Score?
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd has an Innovation Score of 26.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd focus on?
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 6 patents. The company has filed patents in 5 CPC subclasses total.
Is Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd.
What does claim depth mean for Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patents?
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patents average 17.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Shanghai's 6 grants land it in the top 81% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Shanghai ranks #42,824 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.